Biomarkers of IL-33 and sST2 and Lack of Association with Carvedilol Therapy in Heart Failure

Negar Firouzabadi,1– 3 Maryam Dashti,1 Ali Dehshahri,4 Ehsan Bahramali5 1Department of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; 2Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; 3Nonco...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Firouzabadi N, Dashti M, Dehshahri A, Bahramali E
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	heart failure il-33 sst2 carvedilol β-blocker biomarker Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/32f4add3b7ee45ada71592699476ad7e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:32f4add3b7ee45ada71592699476ad7e
record_format	dspace
spelling	oai:doaj.org-article:32f4add3b7ee45ada71592699476ad7e2021-12-02T10:41:22ZBiomarkers of IL-33 and sST2 and Lack of Association with Carvedilol Therapy in Heart Failure1179-1438https://doaj.org/article/32f4add3b7ee45ada71592699476ad7e2020-06-01T00:00:00Zhttps://www.dovepress.com/biomarkers-of-il-33-and-sst2-and-lack-of-association-with-carvedilol-t-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Negar Firouzabadi,1– 3 Maryam Dashti,1 Ali Dehshahri,4 Ehsan Bahramali5 1Department of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; 2Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; 3Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran; 4Department of Pharmaceutical Biotechnology, Shiraz University of Medical Sciences, Shiraz, Iran; 5Digestive Disease Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IranCorrespondence: Negar FirouzabadiDepartment of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, IranTel +98-917-314-5303Fax +98-713-2424128Email nfirouzabadi@yahoo.comObjective: The IL-33/ST2 pathway plays a fundamental role in the cardiovascular system and can be considered as a new therapeutic strategy for the treatment or prevention of cardiovascular diseases. ST2, as an interleukin (IL)-1 receptor family member, has transmembrane (ST2L) and soluble (sST2) isoforms. sST2 neutralizes IL-33 and thereby inhibits the cardioprotective role of IL-33/ST2L signaling pathway. Increase in sST2 level is associated with weak cardiac output and can be a predictor of mortality in heart failure (HF). Thereby, we hypothesized that there may be a relationship between the cardioprotective effects of carvedilol and sST2 and IL-3 in HF patients.Methods: sST2 and IL-33 were measured in serum of 66 individuals; 22 healthy volunteers and 44 suffering from HF; among whom 25 patients received carvedilol and the other 19 patients did not receive any β-blockers.Results: Lack of association between serum levels of IL-33 and sST2 was observed between HF patients and healthy individuals (2.4466 ± 0.69 vs 2.6748 ± 0.33 and 3416.6 ± 1089.1 vs 2971.6 ± 792.5, respectively). Our results indicated no significant difference between sST2 and IL-33 levels in HF patients who did not receive beta-blockers and patients receiving carvedilol (P=0.59 and P=0.97).Conclusion: Our results showed a lack of association between serum levels of IL-33 and sST2 and HF. Moreover, the results do not confirm the cardioprotective mechanism of carvedilol by means of IL-33/sST2 pathway.Keywords: heart failure, IL-33, sST2, carvedilol, β-blocker, biomarkerFirouzabadi NDashti MDehshahri ABahramali EDove Medical Pressarticleheart failureil-33sst2carvedilolβ-blockerbiomarkerTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 12, Pp 53-58 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	heart failure il-33 sst2 carvedilol β-blocker biomarker Therapeutics. Pharmacology RM1-950
spellingShingle	heart failure il-33 sst2 carvedilol β-blocker biomarker Therapeutics. Pharmacology RM1-950 Firouzabadi N Dashti M Dehshahri A Bahramali E Biomarkers of IL-33 and sST2 and Lack of Association with Carvedilol Therapy in Heart Failure
description	Negar Firouzabadi,1– 3 Maryam Dashti,1 Ali Dehshahri,4 Ehsan Bahramali5 1Department of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; 2Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; 3Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran; 4Department of Pharmaceutical Biotechnology, Shiraz University of Medical Sciences, Shiraz, Iran; 5Digestive Disease Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IranCorrespondence: Negar FirouzabadiDepartment of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, IranTel +98-917-314-5303Fax +98-713-2424128Email nfirouzabadi@yahoo.comObjective: The IL-33/ST2 pathway plays a fundamental role in the cardiovascular system and can be considered as a new therapeutic strategy for the treatment or prevention of cardiovascular diseases. ST2, as an interleukin (IL)-1 receptor family member, has transmembrane (ST2L) and soluble (sST2) isoforms. sST2 neutralizes IL-33 and thereby inhibits the cardioprotective role of IL-33/ST2L signaling pathway. Increase in sST2 level is associated with weak cardiac output and can be a predictor of mortality in heart failure (HF). Thereby, we hypothesized that there may be a relationship between the cardioprotective effects of carvedilol and sST2 and IL-3 in HF patients.Methods: sST2 and IL-33 were measured in serum of 66 individuals; 22 healthy volunteers and 44 suffering from HF; among whom 25 patients received carvedilol and the other 19 patients did not receive any β-blockers.Results: Lack of association between serum levels of IL-33 and sST2 was observed between HF patients and healthy individuals (2.4466 ± 0.69 vs 2.6748 ± 0.33 and 3416.6 ± 1089.1 vs 2971.6 ± 792.5, respectively). Our results indicated no significant difference between sST2 and IL-33 levels in HF patients who did not receive beta-blockers and patients receiving carvedilol (P=0.59 and P=0.97).Conclusion: Our results showed a lack of association between serum levels of IL-33 and sST2 and HF. Moreover, the results do not confirm the cardioprotective mechanism of carvedilol by means of IL-33/sST2 pathway.Keywords: heart failure, IL-33, sST2, carvedilol, β-blocker, biomarker
format	article
author	Firouzabadi N Dashti M Dehshahri A Bahramali E
author_facet	Firouzabadi N Dashti M Dehshahri A Bahramali E
author_sort	Firouzabadi N
title	Biomarkers of IL-33 and sST2 and Lack of Association with Carvedilol Therapy in Heart Failure
title_short	Biomarkers of IL-33 and sST2 and Lack of Association with Carvedilol Therapy in Heart Failure
title_full	Biomarkers of IL-33 and sST2 and Lack of Association with Carvedilol Therapy in Heart Failure
title_fullStr	Biomarkers of IL-33 and sST2 and Lack of Association with Carvedilol Therapy in Heart Failure
title_full_unstemmed	Biomarkers of IL-33 and sST2 and Lack of Association with Carvedilol Therapy in Heart Failure
title_sort	biomarkers of il-33 and sst2 and lack of association with carvedilol therapy in heart failure
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/32f4add3b7ee45ada71592699476ad7e
work_keys_str_mv	AT firouzabadin biomarkersofil33andsst2andlackofassociationwithcarvediloltherapyinheartfailure AT dashtim biomarkersofil33andsst2andlackofassociationwithcarvediloltherapyinheartfailure AT dehshahria biomarkersofil33andsst2andlackofassociationwithcarvediloltherapyinheartfailure AT bahramalie biomarkersofil33andsst2andlackofassociationwithcarvediloltherapyinheartfailure
_version_	1718396819004719104

Biomarkers of IL-33 and sST2 and Lack of Association with Carvedilol Therapy in Heart Failure

Ejemplares similares